This statistic displays the projected distribution of cost-sharing for brand name drugs in the Medicare Part D coverage gap in the United States from 2016 to 2020 . In 2016 , five percent of the cost of brand name drugs is expected to be paid by CMS . Provisions of the Affordable Care Act mandate the gradual closure of the Medicare Part D coverage gap through pharmaceutical manufacturer discounts and CMS subsidies .
